HOME > > Products > PRONULIFE® (Probiotic) > PRONULIFE® VagProtect
PRONULIFE® VagProtect
Designed for Intimate Wellness
PRONULIFE® VagProtect is a clinically supported multi-strain probiotic formulation specifically designed to support women’s intimate microbiome balance. It helps maintain a normal vaginal environment, making it suitable for daily intimate care and supporting the overall health of the vaginal microbiota.
The Science Behind Women’s Intimate Health
The vaginal ecosystem naturally harbors more than 50 species of microorganisms, with Lactobacillus species accounting for around 80%. These bacteria secrete acidic substances that help maintain a slightly acidic environment. When the immune system is challenged or intimate care is inadequate, vaginal pH may shift, disrupting the natural microbial balance.
Scientific studies indicate that probiotics, through the gut–vaginal axis, can modulate immune responses, support microbiome balance, and strengthen natural defenses.
Exclusive Multi-Strain Formula with Advanced Microencapsulation Technology
PRONULIFE® VagProtect contains four well-studied Lactobacillus strains:
• Lactobacillus salivarius AP-32
• Lactobacillus rhamnosus F-1
• Lactobacillus rhamnosus CT-53
• Lactobacillus reuteri TE-33
The formulation is protected by Glac’s patented PRONEX® microencapsulation technology, ensuring probiotic stability throughout storage and use.
Scientific Evidence & Regulatory Recognition
• Multiple studies demonstrate its ability to support intimate microbiome balance
• Research shows it helps maintain a normal vaginal environment
• Suitable as a nutritional supplement for daily intimate wellness
• Listed with the Australian Therapeutic Goods Administration (ARTG ID 329111), meeting international safety standards
Why Choose Glac Biotech as Your Probiotic Raw Material & ODM/OEM Partner?
Professional Advantages
• Turnkey ODM/OEM Service – Full support from product development to regulatory compliance
• Patented Formulations & Technology – Exclusive microencapsulation solutions to boost product competitiveness
• Scientific Validation – Backed by extensive studies and publications
• Customization – Flexible solutions tailored for different markets and client needs
Patents
• TWI 451871 – Probiotic composition patent
• TWI 542353 – Probiotic food composition patent
• CN102835657B – Probiotic composition patent (China)
• US9011839B2 – Probiotic composition patent (U.S.)
Start Your Intimate Wellness Journey with PRONULIFE® VagProtect
For more information, please contact us. 📧
Further Reading PRONULIFE® Functional Probiotic Ingredients🔙
Science papers
PRONULIFE® VagProtect is a clinically supported multi-strain probiotic formulation specifically designed to support women’s intimate microbiome balance. It helps maintain a normal vaginal environment, making it suitable for daily intimate care and supporting the overall health of the vaginal microbiota.
The Science Behind Women’s Intimate Health
The vaginal ecosystem naturally harbors more than 50 species of microorganisms, with Lactobacillus species accounting for around 80%. These bacteria secrete acidic substances that help maintain a slightly acidic environment. When the immune system is challenged or intimate care is inadequate, vaginal pH may shift, disrupting the natural microbial balance.
Scientific studies indicate that probiotics, through the gut–vaginal axis, can modulate immune responses, support microbiome balance, and strengthen natural defenses.
Exclusive Multi-Strain Formula with Advanced Microencapsulation Technology
PRONULIFE® VagProtect contains four well-studied Lactobacillus strains:
• Lactobacillus salivarius AP-32
• Lactobacillus rhamnosus F-1
• Lactobacillus rhamnosus CT-53
• Lactobacillus reuteri TE-33
The formulation is protected by Glac’s patented PRONEX® microencapsulation technology, ensuring probiotic stability throughout storage and use.
Scientific Evidence & Regulatory Recognition
• Multiple studies demonstrate its ability to support intimate microbiome balance
• Research shows it helps maintain a normal vaginal environment
• Suitable as a nutritional supplement for daily intimate wellness
• Listed with the Australian Therapeutic Goods Administration (ARTG ID 329111), meeting international safety standards
Professional Advantages
• Turnkey ODM/OEM Service – Full support from product development to regulatory compliance
• Patented Formulations & Technology – Exclusive microencapsulation solutions to boost product competitiveness
• Scientific Validation – Backed by extensive studies and publications
• Customization – Flexible solutions tailored for different markets and client needs
Patents
• TWI 451871 – Probiotic composition patent
• TWI 542353 – Probiotic food composition patent
• CN102835657B – Probiotic composition patent (China)
• US9011839B2 – Probiotic composition patent (U.S.)
Start Your Intimate Wellness Journey with PRONULIFE® VagProtect
For more information, please contact us. 📧
Science papers
- Comparative effect of viable and Heat-Killed Lactic acid Bacteria on immunomodulation. The 6th Asian Conference on Lactic Acid Bacteria. 2011. P-AM11-44. P52..
- Inhibition of in vitro growth of pathogens to protect human mucosa by probiotics. 2012. CIFST P2-18.
- Potential of probiotic strains to modulate the inflammatory responses of epithelial and immune cells in vitro. NEW MICROBIOLOGICA, 2013, P167-179.
- Defense of pathogen infection via modulation of tight junction protein by the probiotic strain L. salivarius ssp.salivarius AP-32. The 6th International Conference on Food Factors. 2015. P-0482.
- Comparison of the inhibition effect of lactic acid bacteria fermentation metabolites on different vaginal pathogens and developing gynecological probiotic products. CIFST. 2017
- Inhibitory effects of viable and heat-killed lactic acid bacteria against different vaginal pathogens: toward development of gynecological probiotics. IUMS.2017
- Bacteriostatic activities of lactic acid bacteria against extended-spectrum β-lactamase(ESBL)-producing Escherichia coli. Basic Clin Pharmacol Toxicol. 2019;125(Suppl. 6):3-4.
- Bacteriostatic abilities of viable and heat-killed lactic acid bacteria against group B Streptococcus. Basic Clin Pharmacol Toxicol. 2019;125:12-13.
- Assessment of bacteriostatic activities of viable and non-viable lactic acid bacteria against methicillin-resistant Staphylococcus aureus. Basic Clin Pharmacol Toxicol. 2019;125:14-15.
